Given the document below, you have to determine if "Yes" or "No", the summary is factually consistent with the document.

Document:
Moderna, Inc.'s revenues from its COVID-19 vaccines have begun an anticipated decline, reflecting the broader trend in drugs and vaccines for SARS-CoV-2 as the pandemic begins to wind down, and it is forecasting a steep drop in coronavirus vaccine sales in 2023. But the messenger RNA-focused biotech's fourth quarter and full year 2022 earnings also hint that the post-pandemic future that it has been building toward is taking shape as newer mRNA-based products inch closer to the market, particularly in infectious diseases like respiratory syncytial virus (RSV) and oncology. Moderna announced its earnings on 23 February, reporting fourth quarter revenues of $5.1bn and full year revenues of $19.3bn, nearly all of which - $4.9bn and $18.4bn, respectively - came from global sales of Spikevax. But the firm is keen to establish itself as a multi-product company. "The company continues to expand at a rapid pace," CEO NAME_1 told Moderna's same-day earnings call. "We now have three commercial COVID-19 vaccine products. We have four programs in Phase III." He added that the company is on track to expand its commercial

Summary:
1. The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023.
2. It is looking ahead to filing for approval of its RSV vaccine.

Is the summary factually consistent with the document? (Yes/No)
Start your an